140 results about "Phosphatidyl Cholines" patented technology

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

The invention discloses a special ultralow-temperature preservative for blood T cells and application of the special ultralow-temperature preservative, and the special ultralow-temperature preservative comprises the following components in percentage by mass and volume: an osmotic pressure regulating system (5-10% of glycerol and 10-20% of glycolalcohol which are compounded); an antioxidant protection system (10%-20% of human serum albumin and 0.1%-1% of glutathione); a nutrition supply agent (a cell culture medium containing glucose, amino acid, vitamin and electrolyte); a pH stable buffer pair (0.5%-3% of HEPES and 0.1%-1% of sodium bicarbonate); and a cell membrane enhancer (1%-1% of cholesterol and 0.05%-0.5% of phosphatidylcholine). The pH value of the preservative is 7.2-7.4, the preservative is suitable for long-time cryopreservation of blood T cells at the ultralow temperature of-80 DEG C to-196 DEG C, and the biological activity and functional integrity of the T cells can be effectively maintained. The invention also relates to an application of the preservative in preparation of T cell preparations preserved at ultra-low temperature, and the survival rate and functional integrity of cells after cryopreservation can be obviously improved.

The invention discloses a composition containing a polypeptide exosome and application of the composition in preparation of a product with skin repair ability, and particularly relates to the technical field of biology, the composition comprises polypeptide-exosome composite nanoparticles, and a polypeptide containing a GRGDS motif and an umbilical cord Wharton's jelly exosome are covalently crosslinked; the lipid double-layer coating layer comprises phosphatidylcholine, cholesterol and PEG-2000, and the molar ratio of the phosphatidylcholine to the cholesterol to the PEG-2000 is 5: 3: 2; the synergist is prepared from 0.1 to 5 percent of epicatechin gallate and 2 to 8 percent of recombinant collagen III oligopeptide. The nano-liposome is prepared through microfluidic self-assembly and a film hydration-ultrasonic intercalation method, and can be loaded on a degradable microneedle patch, so that targeted slow release of a wound part is realized. Through the synergistic effect of targeted delivery, oxidation resistance and collagen regeneration, the skin repair efficiency is remarkably improved, and the healing time is shortened.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention relates to the field of synthetic phospholipids, in particular to a synthetic phosphatidylcholine-like refining method which comprises the following steps: A, dissolving: adding a mixed solvent into synthetic phosphatidylcholine-like, and stirring for dissolving to obtain a crude product solution; b, complexing: adding a metal salt into the crude product solution, mixing, and continuously stirring for dissolving to obtain a primary refined solution; c, crystallization: adding an indissolvable organic solvent into the primary refined liquid, then cooling for crystallization, and carrying out solid-liquid separation to obtain solid crystals; and D, cleaning: rinsing and drying the solid crystal to obtain a refined phosphatidylcholine product. The refining method provided by the invention is green in process and low in cost, and high-purity synthetic phosphatidylcholine with the purity of 98% or above is obtained.

The invention belongs to the technical field of cosmetics, particularly discloses moisturizing nano-liposome emulsion prepared by a microjet method and a preparation method of the moisturizing nano-liposome emulsion, and aims to solve the problems of poor stability of active ingredients, low transdermal absorption efficiency, single effect and non-uniform particle size in a liposome preparation process in the existing moisturizing cosmetics. The nano-liposome emulsion is prepared from glycosylglycerol, acetylchitosamine, tremella polysaccharide, a myrothamnus flabellifolia leaf / stem extract, an artemisia annua extract, a lactobacillus fermentation product, flat nuclear wood oil, hydrogenated lecithin and phosphatidylcholine. The emulsion has excellent moisturizing, soothing and repairing effects, can be used for preparing skin care products such as water aqua, emulsion and cream, and has the advantages of high utilization rate of active ingredients and good stability.

The invention discloses a negative ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the negative ion metabolism marker. The metabolic marker is prepared from any one or more of 7alpha, 17alpha-dimethyl-5beta-androstane-3 alpha, 17beta-diol, N, N-dimethyl phosphatidyl ethanolamine, 15 (S)-hydroxy eicosatrienoic acid and 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine, and the metabolic marker is prepared from any one or more of the following raw materials: 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine. The invention provides a kit which comprises a detection reagent for detecting the negative ion metabolism marker. The invention provides a computer program product for thyroid-related eye diseases. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

The present invention provides a kind of composition containing bird's nest acid, phospholipid and polyunsaturated fatty acid and preparation method thereof, composition, when not adding any additives, bird's nest acid is dispersed in DHA grease in functional ingredients, while solving the problem that DHA is easily oxidized, promotes brain development, regulates immunity, promotes the absorption and utilization of minerals in the intestine and the effects of beauty and skin care. Phospholipids can prevent the sedimentation of bird's nest acid in ω 3 polyunsaturated fatty acid grease, and are phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine. Not only can the sedimentation of bird's nest acid be prevented, but also the growth of nerve cells can be supported, thereby improving the absorption rate of DHA in the brain. Especially PS, itself can not only nourish the brain, enhance brain function, but also relieve mental stress and improve cognition, and is called "brain nutrient".

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

The application discloses a kind of artificial cells for single-cell mass spectrometry and preparation method thereof, wherein artificial cell includes internal water phase, intermediate oil phase and external water phase;Internal water phase includes polyethylene glycol and polyvinyl alcohol aqueous solution, intermediate oil phase includes L-alpha-phosphatidylcholine chloroform and hexane mixture;External water phase includes PVA and F-68 aqueous solution.Compared with natural cell sample, the novel artificial single cell based on microfluidic self-assembly developed in the application has better uniformity, stability and controllability, effectively avoids significant measurement difference between single-cell individual samples, and effectively solves the problem of difficult stable preservation of biological samples.The proposed artificial cell preparation method will largely solve the problem of lack of standard reference material in the field of single-cell mass spectrometry, making the results of single-cell mass spectrometry method more accurate, reliable and mutually recognized.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The application discloses a kind of recombinant collagen glycerol body and preparation method thereof.The recombinant collagen glycerol body is 100 parts by total weight, and is composed of 2.7-3.7 parts of recombinant collagen, 5-15 parts of glycerol, 3.0-4.0 parts of L-alpha-phosphatidylcholine, 0.55-0.75 parts of emulsion regulator cetyl alcohol, 2 parts of preservative 1,2-pentanediol and 0.5 parts of 1,2-hexanediol, 0.05-0.10 parts of thickening agent xanthan gum, 0.1 parts of sodium chloride and 75.05~84.9 parts of purified water, and is prepared by water phase precipitation method.The application uses glycerol body as the carrier of recombinant collagen, which can improve the stability of recombinant collagen on one hand, and promote the transdermal absorption of recombinant collagen on the other hand.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The invention discloses a preparation method of a DNA (deoxyribonucleic acid) vaccine for preventing canine distemper, which comprises the following steps: taking plasmids of genes containing a newly separated canine distemper virus strain, namely a canine distemper virus fusion protein with an amino acid sequence shown as SEQ ID NO.6 and / or a hemagglutinin protein with an amino acid sequence shown as SEQ ID NO.8 as immunogens; hUO, mPEG-DMG, distearoyl phosphatidylcholine and cholesterol are used as lipid materials to prepare the canine distemper lipid nanoparticle DNA vaccine, and the vaccine can effectively stimulate neutralizing antibodies of mice, dogs, foxes and raccoon dogs and has clinical practical prospects.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

This invention discloses a food-grade nanoliposome and its preparation method. Phosphatidylcholine is dissolved in anhydrous ethanol to obtain an organic phase. Ultrapure water or the water-soluble substance 5(6)-carboxyfluorescein is used as the aqueous phase. The organic and aqueous phases are mixed using a microfluidic method or an ethanol injection method to form a uniform lipid film, resulting in nanoliposomes applicable to the food industry. The aqueous phase is encapsulated within the hydrophilic region of the liposome. Since the liposomes prepared by this invention do not contain cholesterol or other substances besides phosphatidylcholine and have a good encapsulation rate, replacing the aqueous phase with nutrients allows for long-term consumption as food without causing excessive cholesterol levels in the human body. Furthermore, the encapsulation of nutrients by liposomes can improve the absorption of nutrients by the human body, demonstrating significant application potential in the food industry.

The embodiments disclosed herein relate to a liposomal composition for sustained release of an active ingredient. In various implementations, the liposomal composition may have a first liposomal core of Phosphatidylcholine (PC), phosphatidylethanolamine (PE), or phosphatidylserine (PS) and the active ingredient dispersed within the first liposomal core. A second core may surround the first liposomal core, with the second core optionally containing one or more polypeptide and a polysaccharide.

The invention relates to the technical field of gel preparations, in particular to ropivacaine phospholipid gel as well as a preparation method and application thereof. The invention provides ropivacaine phospholipid gel. The ropivacaine phospholipid gel is prepared from ropivacaine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the ropivacaine phospholipid gel, the encapsulation effect and the release characteristic of the ropivacaine phospholipid gel are improved by improving phospholipid raw materials and a preparation process.

The invention provides a freeze-dried eye mask and a preparation method thereof, and the freeze-dried eye mask is prepared from the following components in parts by weight: 0.05 to 0.25 part of a glycoside nonionic surfactant, 0.03 to 0.25 part of phosphatidylcholine, 0.01 to 0.04 part of cholesterols, 0.03 to 0.2 part of a mould / saccharomycetes fermentation extraction product, 0.5 to 0.8 part of a humectant, 0.35 to 0.85 part of a skin conditioner, 0.01 to 0.015 part of a thickening agent, 0.25 to 0.4 part of an antiseptic bacteriostatic agent and 0.001 to 0.004 part of an acid-base regulator. Compared with the prior art, the freeze-dried eye mask disclosed by the invention has the advantages that components such as a skin conditioner can be entrapped in vesicles, permeation and absorption of functional components in eye skin can be improved, and the effects of removing wrinkles, whitening and the like are enhanced.

The application belongs to the technical field of pharmaceutical preparations, and discloses a nano-liposome with synergistic effect of double adjuvants and a preparation method and application thereof.The preparation method of the nano-liposome with synergistic effect of double adjuvants comprises the following steps: (1) mixing manganese chloride solution, cationic liposome, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol, cholesterol and a solvent to react, and evaporating to obtain a lipid film; (2) mixing the lipid film, human unmethylated oligodeoxynucleotide and water to heat, and filtering to obtain the nano-liposome with synergistic effect of double adjuvants.The obtained nano-liposome with synergistic effect of double adjuvants has excellent sustained release property.The obtained nano-liposome with synergistic effect of double adjuvants has stable physicochemical properties after being prepared into a nano-liposome vaccine adjuvant, and is convenient to store and transport.

The invention relates to the technical field of gel preparations, in particular to phospholipid gel as well as a preparation method and application thereof. The invention provides phospholipid gel. The phospholipid gel comprises a raw material medicine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the invention, the encapsulation effect and the release characteristic of the phospholipid gel are improved by improving the phospholipid raw material and the preparation process.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The invention belongs to the technical field of organic synthesis, and particularly relates to a polymeric organic base and application of the polymeric organic base in catalytic preparation of a phosphatidylcholine compound. The polymeric organic base disclosed by the invention is a diblock polymer formed by polymerizing a biimidazole guanidine organic tertiary phosphine chain segment and a functional phosphorylcholine chain segment; wherein the biimidazole guanidine organic tertiary phosphine chain segment has strong basicity and can efficiently catalyze the transesterification, and the functionalized phosphorylcholine chain segment is similar to L-alpha-choline alfoscerate in structure and can promote the solubility of organic base and increase the reaction activity at the initial stage of the reaction. The polymeric organic base disclosed by the invention can be used as an immobilized catalyst for preparing phosphatidylcholine compounds from fatty acid ester and L-alpha-choline alfoscerate through transesterification.

The invention is suitable for the technical field of biological medicine, and provides an active composition for relieving fatigue and application of the active composition. The composition is prepared from a silkworm chrysalis-derived mitochondrial repair peptide, a chickpea-derived neuromodulation peptide, a haematococcus pluvialis-derived phagocytosis peptide, a phosphatidylcholine-lipoic acid conjugate, a whey protein-chitosan copolymer and an ergothioneine-selenium compound in a synergistic manner. Through the synergistic effect of four mechanisms of energy metabolism activation, endocrine balance, mitochondrial autophagy repair and oxidative stress removal, physiological fatigue and stress fatigue are effectively and synchronously relieved. After targeted modification, the utilization rate of macamides is remarkably increased, and the composition can remarkably prolong exercise tolerance, reduce cortisol level, promote GABA synthesis, recover mitochondrial function and greatly shorten fatigue recovery time.

A system for the manufacture of pharmaceutical formulations for the treatment of diabetes and diabetic neuropathy, comprising: a) an extraction unit for producing an ethanolic extract from shade-dried leaves of Moringa oleifera Lam. and Bacopa monnieri Linn., and defatting the dried, crushed leaves with petroleum ether to remove lipids and chlorophyll; b) a fractionation unit configured to fractionate the ethanolic extract with ethyl acetate to obtain the ethyl acetate fraction; c) a phytosome preparation unit for the production of phytosomes using antisolvens precipitation technology, wherein the phytosome preparation unit comprises the following: • an ultrasonic device for sonicating a mixture of ethyl acetate fraction and phosphatidylcholine, • a heating device configured to heat the sonicated mixture below 40 °C, and • a condensation device configured to condense solvents into a complex film; and d) a formulation unit configured to incorporate the phytosomes into pharmaceutical dosage forms.